Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw(Massachusetts General Hospital), Leena Gandhi(Dana-Farber Cancer Institute), Shirish M. Gadgeel(Wayne State University), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Jeremy Cetnar(Oregon Health & Science University), Howard West, D. Ross Camidge(University of Colorado Boulder), Mark A. Socinski(University of Pittsburgh Medical Center), Alberto Chiappori(Moffitt Cancer Center), Tarek Mekhail(Florida Hospital Cancer Institute), Bo H. Chao(The Ohio State University), Hossein Borghaei(Fox Chase Cancer Center), Kathryn A. Gold(The University of Texas MD Anderson Cancer Center), Ali Zeaiter(Roche (Switzerland)), Walter Bordogna(Roche (Switzerland)), Bogdana Balas(Roche (Switzerland)), Óscar Puig(Roche (Switzerland)), Volkmar Henschel(Roche (Switzerland)), Sai‐Hong Ignatius Ou(University of California, Irvine)
Cited by 637Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis